Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Plasmacytoma × Lenalidomide × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 74 Lymphoma, Follicular 16 Lymphoma, Large B-Cell, Diffuse 11 Recurrence 9 Lymphoma 7 Neoplasms, Plasma Cell 6 Lymphoma, B-Cell, Marginal Zone 6 Lymphoma, Non-Hodgkin 5 Neoplasms 4 Hematologic Diseases 4 Leukemia, Lymphocytic, Chronic, B-Cell 3 Disease Progression 3 Smoldering Multiple Myeloma 2 Paraproteinemias 2 Lymphoma, Mantle-Cell 2 Sezary Syndrome 1 Prostatic Neoplasms 1 Polycythemia Vera 1 Plasmacytoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Mycosis Fungoides 1 Melanoma 1 Lymphoproliferative Disorders 1 Lymphoma, T-Cell, Cutaneous 1 Limb-girdle muscular dystrophy, type 2C 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Immunoproliferative Disorders 1 Heart Failure 1

Interventions

Dexamethasone 2 daratumumab 1 Lenalidomide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02544308 2022-12-23

IDRIS

University College, London

Phase 3 Active not recruiting

Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡